Davide Pareyson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/887515/publications.pdf

Version: 2024-02-01

284	10,814	34016 52	48187 88
papers	citations	h-index	g-index

293	293	293	9909
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis, natural history, and management of Charcotâ€“Marieâ€“Tooth disease. Lancet Neurology, The, 2009, 8, 654-667.	4.9	475
2	Strikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage. American Journal of Human Genetics, 2012, 90, 1102-1107.	2.6	414
3	Reliability of the CMT neuropathy score (second version) in Charcotâ€Marieâ€Tooth disease. Journal of the Peripheral Nervous System, 2011, 16, 191-198.	1.4	269
4	CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 873-878.	0.9	249
5	Ascorbic acid in Charcotâ€“Marieâ€“Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, The, 2011, 10, 320-328.	4.9	222
6	Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology, 2003, 61, 631-636.	1.5	220
7	Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain, 2005, 128, 1911-1920.	3.7	216
8	Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology, The, 2012, 11, 493-502.	4.9	185
9	Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain, 2008, 131, 2321-2331.	3.7	169
10	Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurology, The, 2009, 8, 158-164.	4.9	155
11	Sensory neuron diseases. Lancet Neurology, The, 2005, 4, 349-361.	4.9	151
12	Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. NeuroMolecular Medicine, 2006, 8, 3-22.	1.8	149
13	New developments in Charcotâ€“Marieâ€“Tooth neuropathy and related diseases. Current Opinion in Neurology, 2017, 30, 471-480.	1.8	145
14	Mutations in CTC1 , Encoding the CTS Telomere Maintenance Complex Component 1, Cause Cerebroretinal Microangiopathy with Calcifications and Cysts. American Journal of Human Genetics, 2012, 90, 540-549.	2.6	141
15	Spinal radiological findings in nine patients with spontaneous intracranial hypotension. Neuroradiology, 2002, 44, 143-150.	1.1	139
16	Validation of the Charcotâ€“Marieâ€“Tooth disease pediatric scale as an outcome measure of disability. Annals of Neurology, 2012, 71, 642-652.	2.8	137
17	Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain, 2009, 132, 426-438.	3.7	135
18	Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain, 2014, 137, 1907-1920.	3.7	133

#	Article	IF	Citations
19	Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPAgene in Italian families. Neurological Sciences, 2004, 25, 130-137.	0.9	131
20	Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology, 1996, 46, 1133-1137.	1.5	118
21	Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. Journal of the Peripheral Nervous System, 2006, 11, 262-271.	1.4	114
22	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscular Disorders, 2000, 10, 391-397.	0.3	112
23	A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. Journal of Neurology, 1990, 237, 339-344.	1.8	108
24	Mitochondrial dynamics and inherited peripheral nerve diseases. Neuroscience Letters, 2015, 596, 66-77.	1.0	103
25	Peripheral neuropathy in mitochondrial disorders. Lancet Neurology, The, 2013, 12, 1011-1024.	4.9	101
26	IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Annals of Neurology, 2005, 57, 180-187.	2.8	100
27	Can MR Imaging Diagnose Adult-Onset Alexander Disease?. American Journal of Neuroradiology, 2008, 29, 1190-1196.	1.2	99
28	Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nature Genetics, 2020, 52, 473-481.	9.4	97
29	Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology, 2000, 54, 1696-1698.	1.5	84
30	Charcot-Marie-Tooth disease and related neuropathies: Molecular basis for distinction and diagnosis. Muscle and Nerve, 1999, 22, 1498-1509.	1.0	83
31	Genotypeâ€“phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in theMPZgene. Brain, 2015, 138, 3180-3192.	3.7	80
32	Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Annals of Neurology, 2000, 47, 104-109.	2.8	79
33	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	1.8	76
34	Epidermal nerve fiber density in sensory ganglionopathies: Clinical and neurophysiologic correlations. Muscle and Nerve, 2001, 24, 1034-1039.	1.0	75
35	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. American Journal of Human Genetics, 2014, 95, 590-601.	2.6	75
36	Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology, 2011, 77, 168-173.	1.5	72

#	Article	IF	Citations
37	Gait pattern classification in children with Charcotâ€“Marieâ€“Tooth disease type 1A. Gait and Posture, 2012, 35, 131-137.	0.6	72
38	Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease. JAMA Neurology, 2016, 73, 645.	4.5	71
39	Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 729-734.	0.9	70
40	Tubule and neurofilament immunoreactivity in human hairy skin: Markers for intraepidermal nerve fibers. Muscle and Nerve, 2004, 30, 310-316.	1.0	66
41	Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome. Journal of the Neurological Sciences, 2007, 263, 100-106.	0.3	64
42	Clinical and molecular studies of 73 Italian families with autosomal dominant cerebellar ataxia type I: SCA1 and SCA2 are the most common genotypes. Journal of Neurology, 1999, 246, 389-393.	1.8	63
43	Relative Frequencies of CAG Expansions in Spinocerebellar Ataxia and Dentatorubropallidoluysian Atrophy in 116 Italian Families. European Neurology, 2000, 44, 31-36.	0.6	63
44	Activation of the Contact System in Cerebrospinal Fluid of Patients with Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 102-108.	0.6	62
45	Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurological Sciences, 2000, 21, 31-37.	0.9	62
46	Vertical supranuclear gaze palsy in Niemann-Pick type C disease. Neurological Sciences, 2012, 33, 1225-1232.	0.9	60
47	Gene dosage effects in hereditary peripheral neuropathy. Neurology, 1997, 49, 1635-1640.	1.5	59
48	Psychometrics evaluation of Charcotâ€Marieâ€Tooth Neuropathy Score (<scp>CMTNSv2</scp>) second version, using Rasch analysis. Journal of the Peripheral Nervous System, 2014, 19, 192-196.	1.4	59
49	Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 810-816.	0.9	59
50	Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurology, The, 2003, 2, 634-635.	4.9	57
51	Balance control in Sensory Neuron Disease. Clinical Neurophysiology, 2007, 118, 538-550.	0.7	57
52	Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscular Disorders, 2008, 18, 19-26.	0.3	55
53	Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment. Journal of the Neurological Sciences, 2016, 363, 182-187.	0.3	55
54	Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurological Sciences, 2004, 25, 72-82.	0.9	51

#	Article	IF	Citations
55	Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 846-863.	0.9	51
56	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	1.4	51
57	Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation. Epilepsia, 2014, 55, e56-9.	2.6	50
58	Natural history of Charcotâ€Marieâ€Tooth disease during childhood. Annals of Neurology, 2017, 82, 353-359.	2.8	50
59	Chloroquine myopathy and myasthenia-like syndrome. Muscle and Nerve, 1988, 11, 114-119.	1.0	48
60	Epidural anaesthesia and spinal arachnoiditis. Anaesthesia, 1989, 44, 317-321.	1.8	47
61	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	3.1	47
62	Four novel cases of periaxin-related neuropathy and review of the literature. Neurology, 2010, 75, 1830-1838.	1.5	47
63	Responsiveness of clinical outcome measures in Charcotâ”Marieâ”Tooth disease. European Journal of Neurology, 2015, 22, 1556-1563.	1.7	47
64	A slowly progressive mitochondrial encephalomyopathy widens the spectrum of AIFM1 disorders. Neurology, 2015, 84, 2193-2195.	1.5	47
65	Neurophysiological Diagnosis of Acquired Sensory Ganglionopathies. European Neurology, 2003, 50, 146-152.	0.6	46
66	Ataxia with oculomotor apraxia type1 (AOA1): novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients. Neurogenetics, 2011, 12, 193-201.	0.7	46
67	Nerve conduction velocity in <scp>CMT</scp>1A: what else can we tell?. European Journal of Neurology, 2016, 23, 1566-1571.	1.7	45
68	Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT. Neurology, 2017, 88, 1445-1453.	1.5	45
69	Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy:in vivoassessment of structural changes. Brain, 2016, 139, 1735-1746.	3.7	44
70	Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). Neurology, 2017, 89, 927-935.	1.5	44
71	Diagnosis of hereditary neuropathies in adult patients. Journal of Neurology, 2003, 250, 148-160.	1.8	43
72	The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Movement Disorders, 2008, 23, 892-895.	2.2	43

#	Article	IF	Citations
73	A novel mutation in the mitochondrial tRNAVal gene associated with a complex neurological presentation. Annals of Neurology, 1998, 43, 98-101.	2.8	42
74	Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. Journal of Neurology, 2009, 256, 1926-1928.	1.8	42
75	Subclinical leukodystrophy and infertility in a man with a novel homozygous CLCN2 mutation. Neurology, 2014, 83, 1217-1218.	1.5	42
76	HMSN III phenotype due to homozygous expression of a dominant HMSN II gene. Neurology, 1992, 42, 2201-2201.	1.5	42
77	Natural history of CMT1A including QoL: A 2-year prospective study. Neuromuscular Disorders, 2008, 18, 199-203.	0.3	40
78	Prevalence and orthopedic management of foot and ankle deformities in Charcotâ€“Marieâ€“Tooth disease. Muscle and Nerve, 2018, 57, 255-259.	1.0	39
79	Hereditary transthyretin amyloidosis overview. Neurological Sciences, 2022, 43, 595-604.	0.9	39
80	Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain, 2020, 143, 3589-3602.	3.7	39
81	Partial laminin ?2 chain deficiency in a patient with myopathy resembling inclusion body myositis. Annals of Neurology, 2000, 47, 811-816.	2.8	37
82	Imaging and outcome in severe complications of lumbar epidural anaesthesia: report of 16 cases. Neuroradiology, 2000, 42, 564-571.	1.1	37
83	Lack of On-Going Adaptations in the Soleus Muscle Activity During Walking in Patients Affected by Large-Fiber Neuropathy. Journal of Neurophysiology, 2005, 93, 3075-3085.	0.9	37
84	Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. Neurological Sciences, 2006, 27, 417-423.	0.9	37
85	Correlation between clinical/neurophysiological findings and quality of life in Charcotâ€Marieâ€Tooth type 1A. Journal of the Peripheral Nervous System, 2008, 13, 64-70.	1.4	37
86	Expanding sialidosis spectrum by genome-wide screening. Neurology, 2014, 82, 2003-2006.	1.5	37
87	Neurogenic muscle hypertrophy. Journal of Neurology, 1989, 236, 292-295.	1.8	36
88	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	1.5	36
89	Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. The Cochrane Library, 2015, 2015, CD011952.	1.5	36
90	Very late onset Friedreich's ataxia without cardiomyopathy is associated with limited GAA expansion in the X25 gene. Neurology, 1997, 49, 1153-1155.	1.5	35

#	Article	IF	Citations
91	A multicenter retrospective study of charcotâ€marieâ€tooth disease type 4B (CMT4B) associated with mutations in myotubularinâ€related proteins (MTMRs). Annals of Neurology, 2019, 86, 55-67.	2.8	35
92	Detection of hereditary neuropathy with liability to pressure palsies among patients with acute painless mononeuropathy or plexopathy. , 1998, 21, 1686-1691.		34
93	PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain, 2014, 137, 1614-1620.	3.7	33
94	Variation in SIPA1L2 is correlated with phenotype modification in Charcotâ€“ Marieâ€“ Tooth disease type 1A. Annals of Neurology, 2019, 85, 316-330.	2.8	33
95	Novel mutations in the HSN2 gene causing hereditary sensory and autonomic neuropathy type II. Neurology, 2006, 66, 748-751.	1.5	32
96	Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. Neurological Sciences, 2008, 29, 193-194.	0.9	32
97	Clinical/Scientific Notes. Neurology, 2011, 77, 1401-1402.	1.5	32
98	Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcotâ€Marieâ€Tooth disease (CMT4). Journal of the Peripheral Nervous System, 2016, 21, 142-149.	1.4	32
99	Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e238.	3.1	32
100	Deletion of the PMP22 gene and hereditary neuropathy with liability to pressure palsies. Current Opinion in Neurology, 1996, 9, 348-354.	1.8	31
101	SETX mutations are a frequent genetic cause of juvenile and adult onset cerebellar ataxia with neuropathy and elevated serum alpha-fetoprotein. Orphanet Journal of Rare Diseases, 2013, 8, 123.	1.2	31
102	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet Journal of Rare Diseases, 2018, 13, 176.	1.2	31
103	Hereditary neuropathy with liability to pressure palsies. Journal of Neurology, 2020, 267, 2198-2206.	1.8	31
104	ATPase Domain <scp>AFG3L2</scp> Mutations Alter <scp>OPA1</scp> Processing and Cause Optic Neuropathy. Annals of Neurology, 2020, 88, 18-32.	2.8	31
105	Expanding the spectrum of genes responsible for hereditary motor neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1171-1179.	0.9	30
106	CSF and Blood Levels of GFAP in Alexander Disease. ENeuro, 2015, 2, ENEURO.0080-15.2015.	0.9	30
107	Rapid progression of late onset axonal Charcot Marie Tooth disease associated with a novel MPZ mutation in the extracellular domain. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1263-1266.	0.9	29
108	GFAP mutations and polymorphisms in 13 unrelated Italian patients affected by Alexander disease. Clinical Genetics, 2007, 72, 427-433.	1.0	29

#	Article	IF	Citations
109	Preferential expression of mutant ABCD1 allele is common in adrenoleukodystrophy female carriers but unrelated to clinical symptoms. Orphanet Journal of Rare Diseases, 2012, 7, 10.	1.2	29
110	An essential role of MAG in mediating axonâ€“myelin attachment in Charcotâ€“Marieâ€“Tooth 1A disease. Neurobiology of Disease, 2013, 49, 221-231.	2.1	29
111	Postural stabilization and balance assessment in Charcotâ€“Marieâ€“Tooth 1A subjects. Gait and Posture, 2014, 40, 481-486.	0.6	29
112	A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology, 2020, 94, e884-e896.	1.5	29
113	Different nerve ultrasound patterns in charcotâ€marieâ€tooth types and hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2018, 57, E18-E23.	1.0	28
114	Natural History and Treatment of Peripheral Inherited Neuropathies. Advances in Experimental Medicine and Biology, 2009, 652, 207-224.	0.8	26
115	Mitochondrial dementia: A sporadic case of progressive cognitive and behavioral decline with hearing loss due to the rare m.3291T>C MELAS mutation. Journal of the Neurological Sciences, 2011, 300, 165-168.	0.3	26
116	Pain and small fiber function in charcotâ€“marieâ€“tooth disease type 1A. Muscle and Nerve, 2014, 50, 366-371.	1.0	26
117	Novel outcome measures for Charcotâˆ’Marieâˆ’Tooth disease: validation and reliability of the 6â€min walk test and StepWatch^{â„¢} Activity Monitor and identification of the walking features related to higher quality of life. European Journal of Neurology, 2016, 23, 1343-1350.	1.7	26
118	F response and somatosensory and brainstem auditory evoked potential studies in HMSN type I and II.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1027-1031.	0.9	25
119	POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation. Neuromuscular Disorders, 2007, 17, 980-982.	0.3	25
120	Hereditary predominantly motor neuropathies. Current Opinion in Neurology, 2009, 22, 451-459.	1.8	25
121	Reliability of instrumented movement analysis as outcome measure in Charcotâ€“Marieâ€“Tooth disease: Results from a multitask locomotor protocol. Gait and Posture, 2011, 34, 36-43.	0.6	25
122	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017.	0.3	25
123	Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. Brain, 2018, 141, 3319-3330.	3.7	25
124	Neurologic symptoms after epidural anaesthesia. Report of three cases. Acta Anaesthesiologica Scandinavica, 1994, 38, 742-743.	0.7	24
125	Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 33-37.	0.9	24
126	Altered <scp>TDP</scp>â€43â€dependent splicing in <scp>HSPB</scp>8â€related distal hereditary motor neuropathy and myofibrillar myopathy. European Journal of Neurology, 2018, 25, 154-163.	1.7	24

#	Article	IF	Citations
127	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	1.1	24
128	Charcot-Marie-Tooth Disease and Related Hereditary Neuropathies: From Gene Function to Associated Phenotypes. Current Molecular Medicine, 2014, 14, 1009-1033.	0.6	24
129	Novel mutations in the GDAP1 gene in patients affected with early-onset axonal Charcot-Marie-Tooth type 4A. Neuromuscular Disorders, 2009, 19, 476-480.	0.3	23
130	A new mutation in GJC2 associated with subclinical leukodystrophy. Journal of Neurology, 2014, 261, 1929-1938.	1.8	23
131	Is overwork weakness relevant in Charcotâ€“Marieâ€“Tooth disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1354-1358.	0.9	23
132	Mutational mechanisms in <scp>MFN2</scp>â€related neuropathy: compound heterozygosity for recessive and semidominant mutations. Journal of the Peripheral Nervous System, 2015, 20, 380-386.	1.4	23
133	Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype. Journal of Neurology, 2019, 266, 2629-2645.	1.8	23
134	Relationship between clinical examination, Quality of Life, disability and depression in CMT patients: Italian Multicenter study. Neurological Sciences, 2008, 29, 157-162.	0.9	22
135	Balance impairment in pediatric charcotâ€“marieâ€“tooth disease. Muscle and Nerve, 2019, 60, 242-249.	1.0	22
136	Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet Journal of Rare Diseases, 2020, 15, 348.	1.2	22
137	Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives. Brain Sciences, 2021, 11, 1447.	1.1	22
138	The effects of wallerian degeneration of the optic radiations demonstrated by MRI. Neuroradiology, 1992, 34, 323-325.	1.1	21
139	Does CMT1A homozygosity cause more severe disease with root hypertrophy and higher CSF proteins?. Neurology, 2003, 60, 1721-1722.	1.5	21
140	Late presentation of leucoencephalopathy with calcifications and cysts: report of two cases. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1303-1304.	0.9	21
141	Posterior column ataxia with retinitis pigmentosa coexisting with sensoryâ€autonomic neuropathy and leukemia due to the homozygous p.Pro221Ser FLVCR1 mutation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 732-739.	1.1	21
142	Clinical and Electrophysiological Aspects of Charcot-Marie-Tooth Disease. NeuroMolecular Medicine, 0, 8, 3-22.	1.8	21
143	Peripheral nerve involvement in Churg-Strauss syndrome. Journal of Neurology, 1992, 239, 317-321.	1.8	20
144	Mild functional effects of a novel GFAP mutant allele identified in a familial case of adult-onset Alexander disease. European Journal of Human Genetics, 2008, 16, 462-470.	1.4	20

#	Article	IF	Citations
145	Xâ€linked Charcotâ€Marieâ€Tooth type 1: strokeâ€like presentation of a novel <scp>GJB1</scp> mutation. Journal of the Peripheral Nervous System, 2014, 19, 183-186.	1.4	20
146	Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 941-952.	0.9	20
147	Charcot-Marie-Tooth Type 2B: A New Phenotype Associated with a Novel RAB7A Mutation and Inhibited EGFR Degradation. Cells, 2020, 9, 1028.	1.8	20
148	The POEMS syndrome: Report of six cases. Italian Journal of Neurological Sciences, 1994, 15, 353-358.	0.1	19
149	Heterozygous Null Mutation in the P 0 Gene Associated with Mild Charcot-Marie-Tooth Disease. Annals of the New York Academy of Sciences, 1999, 883, 477-480.	1.8	19
150	Co-occurrence of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease type 2A in a patient with a novel mutation in the mitofusin-2 gene. Neuromuscular Disorders, 2011, 21, 129-131.	0.3	19
151	Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study. Journal of NeuroEngineering and Rehabilitation, 2013, 10, 65.	2.4	19
152	Transcriptional role of androgen receptor in the expression of long non-coding RNA Sox2OT in neurogenesis. PLoS ONE, 2017, 12, e0180579.	1.1	19
153	Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. Journal of Neuromuscular Diseases, 2019, 6, 201-211.	1.1	19
154	Treadmill training in patients affected by Charcotâ€“Marieâ€“Tooth neuropathy: results of a multicenter, prospective, randomized, singleâ€blind, controlled study. European Journal of Neurology, 2020, 27, 280-287.	1.7	19
155	Symmetry of foot alignment and ankle flexibility in paediatric Charcotâ€“Marieâ€“Tooth disease. Clinical Biomechanics, 2012, 27, 744-747.	0.5	18
156	A novel synonymous mutation in the MPZ gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b. Neuromuscular Disorders, 2016, 26, 516-520.	0.3	18
157	Mitochondrial disorders of the retinal ganglion cells and the optic nerve. Mitochondrion, 2018, 42, 1-10.	1.6	18
158	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	0.9	18
159	Natural history of Charcotâ€“Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life. Neurological Sciences, 2010, 31, 175-178.	0.9	17
160	Early-onset progressive spastic paraplegia caused by a novel TUBB4A mutation: brain MRI and FDG-PET findings. Journal of Neurology, 2016, 263, 591-593.	1.8	17
161	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheimâ€“Chester disease. Journal of Neurology, 2018, 265, 273-284.	1.8	17
162	Dysregulation of myelin synthesis and actomyosin function underlies aberrant myelin in CMT4B1 neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	17

#	Article	IF	Citations
163	Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis. Italian Journal of Neurological Sciences, 1988, 9, 141-145.	0.1	16
164	Parenchymatous neurosyphilis. Neurological Sciences, 2001, 22, 281-282.	0.9	16
165	Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim-Chester disease. Neurological Sciences, 2008, 29, 263-267.	0.9	16
166	Outcome measures for Charcotâ€Marieâ€Tooth disease: clinical and neurofunctional assessment in children. Journal of the Peripheral Nervous System, 2011, 16, 237-242.	1.4	16
167	210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27â€“29 March, 2015, Naarden, The Netherlands. Neuromuscular Disorders, 2015, 25, 802-812.	0.3	16
168	The influence of somatosensory and muscular deficits on postural stabilization: Insights from an instrumented analysis of subjects affected by different types of Charcotâ€“Marieâ€“Tooth disease. Neuromuscular Disorders, 2015, 25, 640-645.	0.3	16
169	PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 870-878.	0.9	16
170	Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies. Expert Review of Neurotherapeutics, 2021, 21, 701-713.	1.4	16
171	Spinal arteriovenous fistula.. Anaesthesia, 1989, 44, 831-833.	1.8	15
172	Efficacy of intranasal administration of neostigmine in myasthenic patients. Journal of Neurology, 1992, 239, 165-169.	1.8	15
173	17p11.2 Duplication Is a Common Finding in Sporadic Cases of Charcot-Marie-Tooth Type 1. European Neurology, 1994, 34, 135-139.	0.6	15
174	Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients. Italian Journal of Neurological Sciences, 1998, 19, 171-175.	0.1	15
175	Propriospinal myoclonus with life threatening tonic spasms as paraneoplastic presentation of breast cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 422-424.	0.9	15
176	Influence of comorbidities on the phenotype of patients affected by Charcotâ€“Marieâ€“Tooth neuropathy type 1A. Neuromuscular Disorders, 2013, 23, 902-906.	0.3	15
177	Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcotâ€Marieâ€Tooth disease. Journal of the Peripheral Nervous System, 2013, 18, 177-180.	1.4	15
178	Brain fluorodeoxyglucose PET in adrenoleukodystrophy. Neurology, 2014, 83, 981-989.	1.5	15
179	Clinical Trials in Spinal and Bulbar Muscular Atrophyâ€”Past, Present, and Future. Journal of Molecular Neuroscience, 2016, 58, 379-387.	1.1	15
180	Human Adipose-Derived Mesenchymal Stem Cells as a New Model of Spinal and Bulbar Muscular Atrophy. PLoS ONE, 2014, 9, e112746.	1.1	15

#	Article	IF	Citations
181	Polyradiculopathy in the course of superficial siderosis of the CNS. Journal of Neurology, 2001, 248, 63-64.	1.8	14
182	A Novel Polymorphic APâ€1 Binding Element of the GFAP Promoter is Associated with Different Allelic Transcriptional Activities. Annals of Human Genetics, 2010, 74, 506-515.	0.3	14
183	Novel lossâ€ofâ€function mutation of the HINT1 gene in a patient with distal motor axonal neuropathy without neuromyotonia. Muscle and Nerve, 2015, 52, 688-689.	1.0	14
184	Repeatability, consistency, and accuracy of handâ€held dynamometry with and without fixation for measuring ankle plantarflexion strength in healthy adolescents and adults. Muscle and Nerve, 2017, 56, 896-900.	1.0	14
185	2017 Peripheral Nerve Society Meeting July 8â€“12, 2017 Sitges, Barcelona, Spain. Journal of the Peripheral Nervous System, 2017, 22, 226-414.	1.4	14
186	Hypomyelinating leukodystrophies in adults: Clinical and genetic features. European Journal of Neurology, 2021, 28, 934-944.	1.7	14
187	Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. International Journal of Molecular Sciences, 2021, 22, 5673.	1.8	14
188	Charcot-Marie-Tooth disease type 2 and P0 gene mutations. Neurology, 1999, 52, 1106-1106.	1.5	14
189	Anti-myeloperoxidase antibodies in Churg-Strauss syndrome. Journal of Neurology, 1993, 240, 449-451.	1.8	13
190	Childhood-onset multifocal motor neuropathy with conduction blocks. Neurology, 2006, 66, 922-924.	1.5	13
191	MYORG -related disease is associated with central pontine calcifications and atypical parkinsonism. Neurology: Genetics, 2020, 6, e399.	0.9	13
192	Guidelines for the diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Italian Journal of Neurological Sciences, 1999, 20, 207-216.	0.1	12
193	Deletion of exons 11-17 and novel mutations of the galactocerebrosidase gene in adult- and early-onset patients with Krabbe disease. Journal of Neurology, 2000, 247, 875-877.	1.8	12
194	Charcotâ€“Marieâ€“Tooth disease type 1A: is ascorbic acid effective?. Lancet Neurology, The, 2009, 8, 1075-1077.	4.9	11
195	An autoinflammatory neurological disease due to interleukin 6 hypersecretion. Journal of Neuroinflammation, 2013, 10, 29.	3.1	11
196	Selective theory of mind impairment and cerebellar atrophy: a case report. Journal of Neurology, 2013, 260, 2166-2169.	1.8	11
197	Adult polyglucosan body disease in a patient originally diagnosed with Fabryâ€™s disease. Neuromuscular Disorders, 2014, 24, 272-276.	0.3	11
198	Pregnancy in Charcot-Marie-Tooth disease. Neurology, 2020, 95, e3180-e3189.	1.5	11

#	Article	IF	Citations
199	Combined central and peripheral acute demyelination. Italian Journal of Neurological Sciences, 1993, 14, 83-86.	0.1	10
200	A novel founder mutation in the MFN2 gene associated with variable Charcot Marie Tooth type 2 phenotype in two families from Southern Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1286-1287.	0.9	10
201	Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 394-400.	1.1	10
202	Alternative Splicing in the HumanPMP22Gene: Implications in CMT1A Neuropathy. Human Mutation, 2016, 37, 98-109.	1.1	10
203	221st ENMC International Workshop:. Neuromuscular Disorders, 2017, 27, 1138-1142.	0.3	10
204	Responsiveness of gait analysis parameters in a cohort of 71 CMT subjects. Neuromuscular Disorders, 2017, 27, 1029-1037.	0.3	10
205	Autophagy and Lysosomal Functionality in CMT2B Fibroblasts Carrying the RAB7K126R Mutation. Cells, 2022, 11, 496.	1.8	10
206	Hereditary motor and sensory neuropathy type I and type II. Italian Journal of Neurological Sciences, 1990, 11, 471-479.	0.1	9
207	Cisplatin neuropathy in brain tumor chemotherapy. Italian Journal of Neurological Sciences, 1992, 13, 311-315.	0.1	9
208	Carbamazepine for paroxysmal distonia due to spinal cord lesions. Italian Journal of Neurological Sciences, 1993, 14, 185-187.	0.1	9
209	Axonal Charcot-Marie-Tooth disease: The fog is only slowly lifting. Neurology, 2007, 68, 1649-1650.	1.5	9
210	Myelin protein zero <scp>Arg36Gly</scp> mutation with very late onset and rapidly progressive painful neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 422-425.	1.4	9
211	Validation of the Italian version of the SBMA Functional Rating Scale as outcome measure. Neurological Sciences, 2016, 37, 1815-1821.	0.9	9
212	Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects. European Journal of Physical and Rehabilitation Medicine, 2019, 55, 47-55.	1.1	9
213	Biopsy-proven primary angiitis of the central nervous system mimicking leukodystrophy: A case report and review of the literature. Journal of Clinical Neuroscience, 2019, 64, 42-44.	0.8	9
214	Spinal epidural abscess complicating tuberculous spondylitis. Italian Journal of Neurological Sciences, 1995, 16, 321-325.	0.1	8
215	Vitamin C and Charcotâ€“Marieâ€“Tooth 1A: Pharmacokinetic considerations. PharmaNutrition, 2013, 1, 10-12.	0.8	8
216	No effect of <scp>AR</scp> polyG polymorphism on spinal and bulbar muscular atrophy phenotype. European Journal of Neurology, 2016, 23, 1134-1136.	1.7	8

#	Article	IF	Citations
217	Hereditary gelsolin amyloidosis (<scp>HGA</scp>): a neglected cause of bilateral progressive or recurrent facial palsy. Journal of the Peripheral Nervous System, 2017, 22, 59-63.	1.4	8
218	Neurofilament light, biomarkers, and Charcot-Marie-Tooth disease. Neurology, 2018, 90, 257-259.	1.5	8
219	Reliability of the <scp>Charcotâ€Marieâ€Tooth</scp> functional outcome measure. Journal of the Peripheral Nervous System, 2020, 25, 288-291.	1.4	8
220	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	1.2	8
221	Dominant Charcotâ€“Marieâ€“Tooth syndrome and cognate disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 817-845.	1.0	7
222	Neuropsychological features of adult form of Alexander disease. Journal of the Neurological Sciences, 2019, 401, 87-89.	0.3	7
223	Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease. Clinical Neurophysiology, 2020, 131, 2440-2451.	0.7	7
224	DNAJB2â€related Charcotâ€Marieâ€Tooth disease type 2: Pathomechanism insights and phenotypic spectrum widening. European Journal of Neurology, 2022, 29, 2056-2065.	1.7	7
225	Immunological Reactivity against Neuronal and Non-Neuronal Antigens in Sporadic Adult-Onset Cerebellar Ataxia. European Neurology, 2009, 62, 356-361.	0.6	6
226	Lower limb areflexia without central and peripheral conduction abnormalities is highly suggestive of Gerstmannâ€“StrÃ¤usslerâ€“Scheinker disease Pro102Leu. Journal of the Neurological Sciences, 2011, 302, 85-88.	0.3	6
227	Pendular nystagmus in progressive ataxia and palatal tremor. Journal of Neurology, 2011, 258, 1877-1879.	1.8	6
228	Effectiveness of valproate for the treatment of manic-like behavior in X-linked adrenoleukodystrophy. Neurological Sciences, 2012, 33, 1197-1199.	0.9	6
229	Pendular nystagmus in hypomyelinating leukodystrophy. Journal of Clinical Neuroscience, 2013, 20, 1443-1445.	0.8	6
230	A novel <scp>NDRG1</scp> mutation in a nonâ€Romani patient with <scp>CMT4D</scp>/<scp>HMSN</scp>â€Lom. Journal of the Peripheral Nervous System, 2017, 22, 47-50.	1.4	6
231	Electromyographic and biomechanical analysis of step negotiation in Charcot Marie Tooth subjects whose level walk is not impaired. Gait and Posture, 2018, 62, 497-504.	0.6	6
232	Are novel outcome measures for Charcotâ€“Marieâ€“Tooth disease sensitive to change? The 6-minute walk test and StepWatchâ„¢ Activity Monitor in a 12-month longitudinal study. Neuromuscular Disorders, 2019, 29, 310-316.	0.3	6
233	Saposin B deficiency as a cause of adult-onset metachromatic leukodystrophy. Neurology, 2019, 93, 310-312.	1.5	6
234	Severe worsening of adult-onset Alexander disease after minor head trauma: Report of two patients and review of the literature. Journal of Clinical Neuroscience, 2020, 75, 221-223.	0.8	6

#	Article	IF	Citations
235	Normal expression of myelin protein zero with frame-shift mutation correlates with mild phenotype. Journal of the Peripheral Nervous System, 2006, 11, 61-66.	1.4	5
236	Quality of life is not impaired in patients with hereditary neuropathy with liability to pressure palsies. European Journal of Neurology, 2007, 14, e45-e46.	1.7	5
237	Adult-onset leukodystrophies from respiratory chain disorders: do they exist?. Journal of Neurology, 2013, 260, 1617-1623.	1.8	5
238	Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS. Annals of Clinical and Translational Neurology, 2020, 7, 1713-1715.	1.7	5
239	Validation of the Italian version of the <scp>Charcotâ€Marieâ€Tooth</scp> disease Pediatric Scale. Journal of the Peripheral Nervous System, 2020, 25, 138-142.	1.4	5
240	European Academy of Neurology guidance for developing and reporting clinical practice guidelines on rare neurological diseases. European Journal of Neurology, 2022, 29, 1571-1586.	1.7	5
241	An update on clinical trials in Charcot-Marie-Tooth Disease. Clinical Investigation, 2014, 4, 221-225.	0.0	4
242	Charcotâ€“Marieâ€“Tooth disease type 2F associated with biallelic HSPB1 mutations. Annals of Clinical and Translational Neurology, 2021, 8, 1158-1164.	1.7	4
243	Chronic Cryptogenic Sensory Polyneuropathy. Archives of Neurology, 2000, 57, 759-760.	4.9	4
244	Recurrent familial neuropathy due to liability to pressure palsies. Italian Journal of Neurological Sciences, 1988, 9, 355-363.	0.1	3
245	PMP22 frameshift mutation and hereditary neuropathy with liability to pressure palsies. Neurology, 1997, 49, 1478-1478.	1.5	3
246	Inherited neuropathies: an update. Journal of Neurology, 2013, 260, 2684-2690.	1.8	3
247	Spinal and bulbar muscular atrophy and Charcotâ€“Marieâ€“Tooth type 1A: Co-existence of two rare neuromuscular genetic diseases in the same patient. Neuromuscular Disorders, 2015, 25, 800-801.	0.3	3
248	Laryngeal and phrenic nerve involvement in a patient with hereditary neuropathy with liability to pressure palsies (HNPP). Neuromuscular Disorders, 2016, 26, 455-458.	0.3	3
249	Lack of benefit of acetyl- dl -leucine in patients with multiple system atrophy of the cerebellar type. Journal of the Neurological Sciences, 2017, 379, 12-13.	0.3	3
250	Validation of the Italian version of the <scp>Charcotâ€Marieâ€Tooth</scp> Health Index. Journal of the Peripheral Nervous System, 2020, 25, 292-296.	1.4	3
251	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. Neurological Sciences, 2020, 41, 2193-2200.	0.9	3
252	Optical coherence tomography in adult adrenoleukodystrophy: a cross-sectional and longitudinal study. Neurological Sciences, 2021, 42, 235-241.	0.9	3

#	Article	IF	Citations
253	CMT2CC associated withNEFHmutations: a predominantly motor neuronopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1.2-1.	0.9	3
254	Detection of hereditary neuropathy with liability to pressure palsies among patients with acute painless mononeuropathy or plexopathy. , 1998, 21, 1686.		3
255	Validation of the Italian version of the pediatric <scp>CMT</scp> quality of life outcome measure. Journal of the Peripheral Nervous System, 2022, 27, 127-130.	1.4	3
256	Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A. Frontiers in Neurology, 0, 13, .	1.1	3
257	Epidural Anesthesia. Neurology, 1997, 48, 293-294.	1.5	2
258	â€œLa toccatinaâ€• polyglottal aphasia in Pirandello. Italian Journal of Neurological Sciences, 1997, 18, 55-57.	0.1	2
259	Slowly progressive sensory hemisyndrome: unusual presentation of paraneoplastic sensory neuronopathy. Journal of the Peripheral Nervous System, 2010, 15, 73-74.	1.4	2
260	Leukoencephalopathy With Predominant Infratentorial Involvement Caused by a Novel ABCD1 Mutation. Neurologist, 2019, 24, 194-197.	0.4	2
261	Association Between Body Mass Index and Disability in Children With Charcot-Marie-Tooth Disease. Neurology, 2021, 97, e1727-e1736.	1.5	2
262	Conduction velocities in Charcotâ€Marieâ€Tooth polyneuropathy type 1. Neurology, 1994, 44, 2216-2216.	1.5	2
263	Homozygous hypertrophic hereditary motor and sensory neuropathies. Italian Journal of Neurological Sciences, 1994, 15, 5-14.	0.1	1
264	Kennedy's disease: clinical and molecular study of two Italian families. Italian Journal of Neurological Sciences, 1995, 16, 467-471.	0.1	1
265	Epidural Anesthesia. Neurology, 1997, 48, 293.	1.5	1
266	Neurologic complications of epidural anesthesia. Italian Journal of Neurological Sciences, 1997, 18, 63-63.	0.1	1
267	Spinal cord lesion due to epidural anesthesia. Neurological Sciences, 2000, 21, 411-412.	0.9	1
268	Development, reliability and validity of the Charcotâ€Marieâ€Tooth disease Pediatric Scale (CMTPedS). Journal of Foot and Ankle Research, 2011, 4, .	0.7	1
269	Clinical neurogenetics: recent advances. Journal of Neurology, 2012, 259, 2255-2260.	1.8	1
270	Coexistence of Charcotâ€Marieâ€Tooth disease type 1A and antiâ€MAG neuropathy. Journal of the Peripheral Nervous System, 2013, 18, 185-188.	1.4	1

#	Article	IF	Citations
271	Longitudinal quantitative magnetic resonance imaging in adrenomyeloneuropathy. European Journal of Neurology, 2019, 26, 1341-1344.	1.7	1
272	Malattie dei nervi periferici. , 2009, , 439-461.		1
273	Case 38-2001: Paraneoplastic Encephalomyelitis and Sensory Ganglioneuropathy. New England Journal of Medicine, 2002, 346, 1029-1030.	13.9	0
274	Superficial siderosis. Neurology, 2007, 68, 623-624.	1.5	0
275	Adult-onset leukoencephalopathy with calcifications associated with primary antiphospholipid syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1215-1217.	0.9	0
276	P60 Variable severity of early onset CMT2 with compound heterozygous MFN2 mutations. Neuromuscular Disorders, 2010, 20, S21.	0.3	0
277	Authorsâ€™ response to Rahman and Fontes. PharmaNutrition, 2013, 1, 101.	0.8	0
278	Memory loss: do not forget the mammillary bodies. Neurological Sciences, 2014, 35, 473-474.	0.9	0
279	The role of androgen receptor gene variants on SBMA phenotype. Journal of the Neurological Sciences, 2015, 357, e231.	0.3	0
280	Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area. Orphanet Journal of Rare Diseases, 2015, 10, .	1.2	0
281	Leukodystrophies. , 2015, , 163-175.		0
282	Asymptomatic adrenoleukodystrophy in elderly males. Journal of Neurology, 2020, 267, 1849-1851.	1.8	0
283	A novel founder mutation in the MFN2 gene associated with variable Charcot-Marie-Tooth type 2 phenotype in two families from Southern Italy. BMJ Case Reports, 2009, 2009, bcr0820080652-bcr0820080652.	0.2	0
284	Charcotâ€Marieâ€Tooth disease in Africa. Journal of the Peripheral Nervous System, 2022, 27, 98-99.	1.4	0